Snehal Patel Buys 5,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 5,500 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was acquired at an average cost of $13.18 per share, for a total transaction of $72,490.00. Following the purchase, the chief executive officer now owns 5,532,602 shares in the company, valued at $72,919,694.36. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Tuesday, July 23rd, Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $15.89 per share, for a total transaction of $23,835.00.
• On Thursday, June 13th, Snehal Patel purchased 174,825 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $14.30 per share, for a total transaction of $2,499,997.50.

Greenwich LifeSciences Trading Up 1.3 %

GLSI traded up $0.18 during mid-day trading on Wednesday, hitting $14.36. 3,086 shares of the stock were exchanged, compared to its average volume of 44,654. The firm’s fifty day moving average is $15.51 and its two-hundred day moving average is $14.32. Greenwich LifeSciences, Inc. has a 1-year low of $7.58 and a 1-year high of $21.44. The company has a market cap of $184.96 million, a PE ratio of -19.69 and a beta of 1.64.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its earnings results on Monday, May 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. As a group, research analysts anticipate that Greenwich LifeSciences, Inc. will post -0.75 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of Greenwich LifeSciences in a research note on Wednesday, May 22nd.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds have recently bought and sold shares of GLSI. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter valued at about $264,000. Rhumbline Advisers acquired a new stake in Greenwich LifeSciences in the 2nd quarter valued at about $117,000. Finally, Vanguard Group Inc. raised its position in Greenwich LifeSciences by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after purchasing an additional 1,420 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.